Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarey Drugs & Pharmaceuticals has submitted to the exchanges the newspaper copies of its audited financial results for the quarter and year ended March 31, 2025, as required under SEBI's Listing Regulations. The results were published in 'Active Times' (English) and 'Mumbai Lakshwadeep' (Marathi) on June 1, 2025, after being approved by the Board on May 30, 2025. For FY25, total income rose to ₹48,375.57 lakhs from ₹40,258.28 lakhs in FY24, an increase of about 20%. However, profit before tax declined to ₹402.39 lakhs from ₹468.37 lakhs, a drop of roughly 14%. Q4 FY25 performance was notably weak, with PBT falling sharply to ₹47.01 lakhs from ₹215.19 lakhs in Q4 FY24. Full-year EPS stood at ₹1.84, flat compared to the previous year.
This is a routine regulatory filing confirming that the audited results, already disclosed earlier, were published in newspapers as mandated. The underlying numbers point to revenue growth but margin compression and a weak Q4, which is mildly negative but largely priced in since results were already known.